Intellia Therapeutics, a biopharmaceutical company specializing in CRISPR gene editing, announced its participation in three upcoming investor conferences: Bank of America Securities Health Care Conference on May 12, RBC Capital Markets Global Healthcare Conference on May 20, and Jefferies Global Healthcare Conference on June 3, 2026. The company's management will engage in fireside chats at these events, which will be webcast live and available for replay. This participation highlights Intellia's ongoing efforts to engage with investors and showcase its advancements in gene editing technology and clinical development.
YD Bio Limited's U.S. affiliate, EG BioMed US, has secured clinical lab licenses in Rhode Island and Pennsylvania, expanding its CLIA-certified, CAP-accredited lab's footprint to 46 states plus D.C. and Guam. This expansion enhances patient access to...
Vivani Medical's wholly owned subsidiary Cortigent will merge with Nasdaq-listed ClearOne, which will be renamed Cortigent Holdings and trade under the ticker CRGT. Vivani will own a majority stake in the combined company, which will focus on advanci...
Diffusion, a global communications agency, is growing its home and interiors portfolio by signing new clients including POVISON (furniture), LUSA Lighting, and Induction Hardware (appliances). The agency will support these premium brands with integra...
Heathrow Finance PLC announced a €350 million offering of 4-year senior secured notes with a stabilization period starting July 2, 2026, and ending by August 7, 2026. BNP Paribas and other major banks will manage the stabilization to support the bond...
Polibeli Group Ltd. has signed a non-binding Memorandum of Understanding with AUTHAIKAM COMPANY LIMITED to jointly evaluate a potential 100 MW AI computing center project in Thailand. The collaboration involves preliminary assessments such as site vi...
